Asparaginase in the Treatment of Acute Lymphoblastic Leukemia in Adults: Current Evidence and Place in Therapy
DOI: https://doi.org/10.2147/BLCTT.S342052
2022-05-30
Blood and Lymphatic Cancer: Targets and Therapy
Abstract:Krishna R Juluri, 1– 3 Chloe Siu, 3, 4 Ryan D Cassaday 1– 3 1 Department of Medicine, University of Washington School of Medicine, Seattle, WA, USA; 2 Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA; 3 Seattle Cancer Care Alliance, Seattle, WA, USA; 4 Department of Pharmacy, University of Washington School of Pharmacy, Seattle, WA, USA Correspondence: Ryan D Cassaday, Email Acute lymphoblastic leukemia (ALL) is a rare hematologic malignancy resulting in the production of abnormal lymphoid precursor cells. Occurring in B-cell and T-cell subtypes, ALL is more common in children, comprising nearly 30% of pediatric malignancies, but also constitutes 1% of adult cancer diagnoses. Outcomes are age-dependent, with five-year overall survival of greater than 90% in children and less than 20% in older adults. L-asparaginase, an enzyme not found in humans, depletes serum levels of L-asparagine. As leukemic cells are unable to synthesize this amino acid, its deprivation results in cell death. The success of asparaginase-containing regimens in the treatment of pediatric ALL, and poor outcomes with conventional cytotoxic regimens in adults, have led to trials of pediatric or pediatric-inspired regimens incorporating asparaginase in the adolescent and young adult (AYA) and adult populations. Initially purified from Escherichia coli , newer formulations of asparaginase have been developed to address short half-life, high immunogenic potential, and manufacturing difficulties. Unfamiliarity with asparaginase use and management of its unique toxicities may result in treatment-decisions that negatively impact outcomes. In this review, we address the current use of asparaginase in the treatment of ALL, with an emphasis on its role in the treatment of adults, key clinical trials, recognition and management of toxicities, and ongoing directions of study. Keywords: acute lymphoblastic leukemia, ALL, adult, asparaginase, pegaspargase Acute lymphoblastic leukemia (ALL) is a hematologic malignancy of lymphoid precursor cells occurring in B- and T-cell subtypes. While it is the most common childhood malignancy, comprising up to 30% of pediatric cancer and 80% of pediatric leukemia diagnoses, it is relatively rare among adults, comprising 15–20% of adult leukemia cases and less than 1% of adult cancer diagnoses in the United States (US). 1 Historically, significantly better outcomes have been seen in pediatric patients, with a five-year overall survival (OS) of nearly 90% in children, and less than 20% for older patients. This is thought to be due in part to the regimens used in the pediatric population, which generally include agents with more frequent and longer durations of administration, though differences in host and disease factors between the two groups are also likely contributory. Non-randomized studies also noted that adolescent and young adults (AYA) treated by pediatricians with expertise in these regimens had better outcomes than those treated by adult oncologists. 2–7 These findings have led to further trials of pediatric or pediatric-inspired regimens in AYA and adult patients. L-asparaginase is a central component of most modern pediatric ALL regimens. Therefore, the migration of pediatric strategies into the management of adults with ALL will lead to the wider utilization of this class of agents in this population. Here, we review the role of asparaginase in the treatment of ALL, with an emphasis on its use in the AYA and adult population, the various formulations currently available, its unique side-effect profile, management of treatment-related toxicity, and ongoing clinical trials. The first studies implicating L-asparaginase as an anti-leukemic agent were conducted in the 1950s and 1960s. Kidd 8 demonstrated that guinea pig serum could induce regression of explanted lymphomas in mice and rats, with a subsequent series of studies identifying L-asparaginase as the serum component responsible for this effect. 9–13 The first documented use of L-asparaginase in humans came in 1966. Dolowy 14 reported a case of a pediatric patient with multiply relapsed ALL who was administered L-asparaginase partially purified from guinea pig serum. While improvement of clinical and laboratory parameters was noted, the patient developed significant toxicity immediately following infusion, including a likely hypersensitivity reaction, and succumbed to pulmonary hemorrhage ten days after administration. In a 1967 case series, Hill reported 15 on three pediatric patients with ALL treated with purified L-asparaginase, all of whom exhibited clinical and laboratory improvement, with one achieving complete remission (CR). These preliminary reports led -Abstract Truncated-